PARP inhibitors in prostate cancer: time to narrow patient selection?

Mark C. Markowski; Emmanuel S. Antonarakis

doi:10.1080/14737140.2020.1781622

PARP inhibitors in prostate cancer: time to narrow patient selection?

Mark C. Markowski, Emmanuel S. Antonarakis

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	523-526
Number of pages	4
Journal	Expert Review of Anticancer Therapy
DOIs	https://doi.org/10.1080/14737140.2020.1781622
State	Published - 2020
Externally published	Yes

Bibliographical note

Funding Information:
This work was partially supported by National Institutes of Health Cancer Center Support Grant P30CA006973 (E.S.A.) and a Prostate Cancer Foundation Young Investigator Award (M.C.M).

Keywords

PARP inhibitors
metastatic castration-resistant prostate cancer
niraparib
olaparib
prostate cancer
rucaparib
talazoparib

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1080/14737140.2020.1781622

Find It

Find It at U of M Libraries

Cite this

@article{90da21c5cdf448cf97d9fa36da2e36c9,

title = "PARP inhibitors in prostate cancer: time to narrow patient selection?",

keywords = "PARP inhibitors, metastatic castration-resistant prostate cancer, niraparib, olaparib, prostate cancer, rucaparib, talazoparib",

author = "Markowski, {Mark C.} and Antonarakis, {Emmanuel S.}",

note = "Funding Information: This work was partially supported by National Institutes of Health Cancer Center Support Grant P30CA006973 (E.S.A.) and a Prostate Cancer Foundation Young Investigator Award (M.C.M).",

year = "2020",

doi = "10.1080/14737140.2020.1781622",

language = "English (US)",

pages = "523--526",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - PARP inhibitors in prostate cancer

T2 - time to narrow patient selection?

AU - Markowski, Mark C.

AU - Antonarakis, Emmanuel S.

N1 - Funding Information: This work was partially supported by National Institutes of Health Cancer Center Support Grant P30CA006973 (E.S.A.) and a Prostate Cancer Foundation Young Investigator Award (M.C.M).

PY - 2020

Y1 - 2020

KW - PARP inhibitors

KW - metastatic castration-resistant prostate cancer

KW - niraparib

KW - olaparib

KW - prostate cancer

KW - rucaparib

KW - talazoparib

UR - http://www.scopus.com/inward/record.url?scp=85087819908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087819908&partnerID=8YFLogxK

U2 - 10.1080/14737140.2020.1781622

DO - 10.1080/14737140.2020.1781622

M3 - Editorial

C2 - 32521178

AN - SCOPUS:85087819908

SN - 1473-7140

SP - 523

EP - 526

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

ER -

PARP inhibitors in prostate cancer: time to narrow patient selection?

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Cite this